NCT02402036View on ClinicalTrials.gov

A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Colon Cancer
Interventions
DRUG

Regorafenib

Regorafenib orally for 21 days every 28 day cycle

Trial Locations (1)

20007

Georgetown University, Washington D.C.

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Georgetown University

OTHER